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Background: While safe intravenous (IV) use of levodopa has been documented for
over 50 years, regulatory supervision for pharmaceuticals given by a route other than
that approved by the U.S. Food and Drug Administration (FDA) has become increasingly
cautious. If delivering a drug by an alternate route raises the risk of adverse events, an
investigational new drug (IND) application is required, including a comprehensive review
of toxicity data.
Methods: Over 200 articles referring to IV levodopa were examined for details of
administration, pharmacokinetics, benefit, and side effects.
Results: We identified 142 original reports describing IVLD use in humans, beginning
with psychiatric research in 1959–1960 before the development of peripheral
decarboxylase inhibitors. At least 2760 subjects have received IV levodopa, and reported
outcomes include parkinsonian signs, sleep variables, hormone levels, hemodynamics,
CSF amino acid composition, regional cerebral blood flow, cognition, perception and
complex behavior. Mean pharmacokinetic variables were summarized for 49 healthy
subjects and 190 with Parkinson’s disease. Side effects were those expected from clinical
experience with oral levodopa and dopamine agonists. No articles reported deaths or
induction of psychosis.
Conclusion: At least 2760 patients have received IV levodopa with a safety profile
comparable to that seen with oral administration.
Keywords: levodopa, intravenous, Parkinson, DOPA, pharmacokinetics, carbidopa, FDA, IND
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INTRODUCTION

METHODS

Impairments in dopaminergic neurotransmission in the basal
ganglia are a hallmark of Parkinson disease (PD), the second most
common neurodegenerative disease. Replacement of dopamine
has been the cornerstone of treatment for PD. Because dopamine
itself does not cross the blood-brain barrier (BBB), its immediate
precursor levodopa (L-3,4-dihydroxphenylalanine, L-DOPA) is
administered since it crosses the BBB (Hornykiewicz, 1963;
Cotzias et al., 1967; Birkmayer and Hornykiewicz, 2001).
Although purified levodopa was first ingested by mouth in 1913
(Roe, 1997), it was first used for medical treatment by intravenous
(IV) rather than oral administration (Pare and Sandler, 1959;
Birkmayer and Hornykiewicz, 2001).
Oral levodopa has become the preferred method of treatment
clinically, but IV levodopa administration still holds advantages
over the oral form for some purposes. First, the rapid
administration of IV levodopa is often necessary for certain
study designs, including those focused on the pharmacokinetics
and pharmacodynamics of the drug. Additionally, the IV route
leads to more predictable plasma levodopa concentration because
oral medications have highly variable absorption characteristics,
especially in PD patients (Bushmann et al., 1989), with
differences in absorption based on sex and age (Robertson
et al., 1989; Kompoliti et al., 2002). IV administration also
permits researchers to keep brain levodopa concentrations
constant while assessing physiological responses over time.
Recent years have seen increasing interest in potential benefits
of continuous dopaminergic stimulation in the treatment of
PD (Jenner et al., 2011). Continuous stimulation helps avoid
wearing off of motor benefit during levodopa nadirs, and
there is also some evidence that it may reduce the risk of, or
mitigate, dyskinesias and other peak-dose side effects. Thus,
IV levodopa may prove useful for human studies investigating
the pathophysiology of continuous vs. pulsatile dopaminergic
stimulation in humans. Finally, IV levodopa is sometimes used
clinically in patients who cannot tolerate oral medications,
such as PD patients during surgery or on total parenteral
nutrition.
Current U.S. FDA regulations focus heightened scrutiny on
research in which drugs are delivered by a route for which the
drug has not been approved. Predictably, in addition to any safety
benefits, the heightened scrutiny has created practical obstacles
to research with IV levodopa, as described for instance by
Rascol et al. (2001, p. 250). Specifically, an IND (Investigational
New Drug) application must be submitted if the risks of IV
administration significantly exceed those of oral levodopa [§21
CFR 312.2(b)(iii)]. Therefore, the overall goal of this paper
is to determine whether or not IV levodopa carries risks
greater than oral administration by compiling a literature review
that comprehensively summarizes the human experience with
intravenously administered levodopa. We tabulate the extent of
human exposure, side effects, benefits, and efficacy. We also
summarize pharmacokinetic (PK) and pharmacodynamic (PD)
parameters from these studies. These data should help inform
decisions about whether IV administration of levodopa requires
an IND.

The authors searched MEDLINE and OVID, reviewed selected
books, searched toxicity databases, and followed references cited
in those sources. Articles written completely in languages other
than English, French, German, Italian, Spanish, or Portuguese
were excluded. Search terms included (levodopa/L-dopa/DOPA)
AND (intravenous/intravascular/infusion/injection/i.v.); limit to
humans; search date through May, 2015. Studies using oral or
intraduodenal l-DOPA administration were excluded except for
PK/PD studies cited in Table 2. Studies in which IV levodopa
was always coadministered with monoamine oxidase inhibitors
(MAOIs) or catechol-O-methyltransferase (COMT) inhibitors
were excluded. Levodopa methyl ester (Juncos et al., 1987) and
d,l-DOPA (Pare and Sandler, 1959) were included, but PK/PD
calculations were corrected for the difference in molecular
weights. Co-administered drugs were reported if included by the
authors.
We recorded total dose and maximum infusion rate. We
also recorded pharmacokinetic (PK) and pharmacodynamic
(PD) parameters where available, including steady state volume
of distribution (VOD), clearance, distribution half life (t½α ),
elimination half life (t½ or t½β ), Emax , and EC50 . Reported
data were used to calculate any missing PK parameters where
possible. Additionally, any reports on efficacy were noted. Side
effect frequency was recorded if reported. The number of subjects
and subject conditions (Parkinson disease, other disease states
or healthy volunteers) were recorded for each study. Average
PK parameters were calculated across studies, weighted by the
number of subjects.
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RESULTS
One hundred forty-two articles reporting intravenous levodopa
administration were identified. Most subjects with parkinsonism
were diagnosed with idiopathic PD, but some studies reported
a variety of etiologies including postencephalitic and vascular
parkinsonism and PSP. PD patients differed in their history
of prior drug treatment before the studies with conditions
including de novo, fluctuating, on-off, and stable. Some subjects
were treated with levodopa for conditions other than PD
(see Table 1: Patient Populations and Response Parameters),
including other movement disorders (dystonia, progressive
supranuclear palsy [PSP], neuroleptic malignant syndrome
[NMS], primary psychiatric disorders (schizophrenia, mood
disorders, personality disorders), endocrine disorders (diabetes
mellitus, essential obesity, hypopituitarism), hepatic disease
(alcoholic cirrhosis, steatohepatitis, hepatic encephalopathy),
cardiac valvular disease, and asthma. Healthy controls were also
included in some studies.
Pharmacokinetic data were reported for a total of 251
human subjects (see Table 2: Pharmacokinetics of Levodopa).
Co-administration of a peripheral decarboxylase inhibitor (PDI)
lowered the clearance and increased the elimination half-life
of intravenously administered levodopa, while there was no
notable effect of PDIs on volume of distribution. Additional
PK data are available from studies that gave levodopa by
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clearance and volume of distribution (as mentioned above),
minimized gastrointestinal symptoms, and allowed subjects
to be given lower doses of levodopa. Other concomitant
drugs are listed, to help explain any side effects that might
be caused by concomitant drug administration or an
interaction with levodopa rather than by levodopa alone.
These include adenosine receptor antagonists (istradefylline,
tozadenant [SYN115], aminophylline, caffeine), stimulants
(amphetamines, methylphenidate), dopamine receptor agonists
(apomorphine, terguride, SKF38393), monoamine oxidase
(MAO) inhibitors, dextromethorphan, estradiol, paroxetine, and
dantrolene.
A variety of neurological, psychiatric, cardiovascular, and
other physiological effects of levodopa were monitored (see
Table 1). There were no reported deaths. There were no
instances of psychosis, even when attempting to elicit it in
susceptible subjects (Goetz et al., 1998). There were also no
life-threatening events (serious adverse effects) following IV
levodopa administration at high doses, regardless of whether
a PDI was co-administered. With co-administration of a PDI,
the dosage range causing side effects (mainly nausea and
asymptomatic hypotension) was 45–150 mg as a single bolus
or infusions of 0.5–2.0 mg/kg/h. Without a co-administered
PDI, side effects were reported with a bolus of 60–200 mg or
an infusion of 1.5–3.0 mg/kg/hr. Side effects were more likely
with higher doses, but other factors such as age, sex, disease
severity, and prior treatment also played a role in side effects of
levodopa.
Other than these side effects found at high doses, several
milder or less frequent side effects were reported. These
primarily included mild autonomic changes (orthostasis
and tachycardia), psychiatric changes (sedation, anxiety,
insomnia, and improvement in mood), and neurologic effects
(improvements in tics, REM sleep changes, subjective weakness,
headaches, and increased dyskinesias). Various other effects were
noted in isolated reports (listed in Table 3). It is important to
note that both side effects and efficacy depended strongly on
subject factors including gender, age, past treatment, and disease
state. Also, dsykinesia was mentioned as a side effect only in
patients with PD, and most often in those with a long history of
previous levodopa treatment.
Motor benefits of levodopa in PD have been demonstrated
conclusively. Additional reported benefits of IV levodopa
treatment in PD included improved sleep (Hardie et al.,
1984) and attenuation of early morning akinesia or dystonia
(Juncos et al., 1987). In other patient groups, benefits of
IV levodopa included improvement of the comatose state in
hepatic encephalopathy (Abramsky and Goldschmidt, 1974)
and improvement in depressive and somatoform symptoms
(Ingvarsson, 1965a). One report found it more effective
than dantrolene for treating neuroleptic malignant syndrome
(Nisijima et al., 1997). More recently, IV levodopa treatment
was found to alleviate the neuropsychiatric adverse effects
associated with interferon-alpha, namely lethargy, hypersomnia,
depression, agitation, akathisia, and confusion (Sunami et al.,
2000).

TABLE 1 | Patient populations and response parameters.
Patient populations

Response parameters

Healthy volunteers

Vital signs:

Movement disorders:
Parkinson’s (de novo, stable,
fluctuators, on-off)

Heart rate, blood pressure,
temperature, respirations
Cardiovascular:

Progressive supranuclear palsy

ECG

Parkinson’s disease psychosis

Cerebral blood flow

Carcinoma of the rectum

Renal:

Stereotactic surgery

Urine flow

Post-menopausal women

Urinary sodium excretion

Tourette syndrome/tic disorders
Asthma
Schizophrenia
Mood disorders:

Potassium excretion
Plasma renin activity
Renal plasma flow
Metabolism:

Mild to moderate depression

Urinary metabolite excretion

Treatment-resistant depression

Cerebral metabolism

Bipolar depression
Cyclothymic disorder
Borderline personality disorder

Plasma metabolites
CSF amino-acid composition
PD motor improvement

Neuroleptic malignant
syndrome

Unified Parkinson’s disease rating

Hepatic disorders:

Dyskinesias

scale (UPDRS), walking, tapping, etc.

Alcoholic cirrhosis

Tic improvement

Steatohepatitis

Neuropsychiatric:

Hepatic encephalopathy
Endocrine disorders:
Diabetes mellitus

Cognition
Mood
Behavior

Essential obesity

Psychosis

Hypopituitarism

Dementia

Cardiovascular disease:
Atrial septal defect
Rheumatic valvular disease

EEG (including REM sleep EEG)
Endocrine:
Prolactin, HGH, ACTH, LH,
vasopressin

Subject populations given IV levodopa and responses to drug measured in studies listed
in Table 3.

other routes (Sasahara et al., 1980a; Poewe, 1993; Muhlack
et al., 2004; LeWitt et al., 2009), and several studies report
the bioavailability of oral doses relative to IV administration
(Sasahara et al., 1980b; Robertson et al., 1989; Kompoliti et al.,
2002).
The pharmacodynamic data (see Table 3: Reports of Human
Experience with IV Levodopa) represent a total of 2760 human
subjects, with a significant variety of patient groups and a
multitude of response parameters (see Table 1). No side effects
were reported for 1260 subjects. The highest total IV dose was
4320 mg in 1 day, given to a patient with idiopathic PD and
carcinoma of the retina. The patient reported no adverse effects
at this dose. The highest reported single bolus dose was 200 mg,
and the highest infusion rate was 5.0 mg/kg/h.
Concomitantly administered peripheral decarboxylase
inhibitors included carbidopa and benserazide. PDIs affected
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TABLE 2 | Pharmacokinetics of levodopa.
References

Patient group

Clearance

Volume of

Elimination

Distribution

Oral

distribution

half-life

half-life

bioavailability

n

Mean (L/kg/h)

n

Mean (L/kg)

n

Mean (h)

50

2.44

50

1.05

n

Mean (h)

Birkmayer et al., 1973

PD

50

1.61

Bredberg et al., 1990

Fluctuating

5

0.37

Chan et al., 2004

De novo

12

0.36

12

0.63

12

2.25

12

0.17

Chronic

12

0.35

12

0.49

12

1.47

12

0.17

“Slow” CD absorption

5

1.18

“Rapid” CD absorption

4

1.15
1.44

Durso et al., 2000

Fabbrini et al., 1987

De novo

4

0.13

4

0.26

4

Stable

6

0.11

6

0.22

6

1.41

Wearing-Off

6

0.13

6

0.30

6

1.67

On-off

12

0.13

12

0.30

12

1.54

Hardie et al., 1986a

Fluctuating

7

1.14

7

2.63

7

1.60

7

0.13

Gancher et al., 1987b

De novo

5

0.34

5

0.56

5

1.70

5

0.10

Stable

4

0.33

4

0.62

4

1.80

4

0.11

Fluctuating

11

0.32

11

0.65

11

2.00

11

0.10

Nutt et al., 1985

2 h IV

7

0.55

7

0.67

7

1.38

7

0.07

(all PD, fluctuating)

2 h IV + PDI

7

0.30

7

0.80

7

2.01

7

0.11

≥20 h IV

4

0.52

4

0.88

4

1.19

4

0.11

≥20 h IV + PDI

4

0.28

4

1.09

4

2.60

4

0.33

De novo

8

0.44

8

0.75

8

1.60

Stable

12

0.42

12

0.75

12

1.70

Fluctuating

9

0.39

9

0.63

9

1.50

Nutt et al., 1992

n

Mean (unitless)

0.63

Poewe, 1993e

PD

Roberts et al., 1995c, d

Healthy

8

0.37

8

1.13

8

2.15

Healthy + selegine

8

0.37

8

2.01

8

3.78

Healthy elderly

9

0.85

9

1.01

9

0.82

9

Healthy young

8

1.40

8

1.65

8

0.82

8

0.41

Healthy elderly + PDI

8

0.35

8

0.62

8

1.23

8

0.85

Healthy young + PDI

8

0.56

8

0.93

8

1.16

8

0.86

Sasahara et al., 1980bf

PD

5

1.38

5

1.29

5

0.65

5

0.33

Stocchi et al., 1992

Intravenous bolus

6

0.97

6

0.96

6

0.83

(all “on-off”)

Intravenous infusions

2

0.63

2

0.82

2

0.90

Robertson et al., 1989c

Total n
Weighted mean

1.40

212

3.00

242

1.50

251

0.719 L/kg/h

1.18 L/kg

0.09

73
1.50 h

16 (PDI) 22 (no PDI)
0.14 h

0.86 (PDI) 0.48 (no PDI)

Summary of pharmacokinetic parameters with weighted means.
a Assumed mean weight to be 70 kg for VOD.
b Values read from graphs.
c Half-life estimated from relationship: clearance = (ln 2 * VOD)/ elim. T1/2.
d Assumed mean weight to be 70 kg for clearance.
e From a table with no additional data provided; not included in weighted mean calculations of pharmacokinetic parameters.
f VOD estimated from relationship: clearance = (ln 2 * VOD)/ elim. T1/2.
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5

15

1

Birkmayer and Mentasti,
1967

Birkmayer, 1967

132

PD

PD

PD

Not given

Birkmayer and
Hornykiewicz, 1962

Moderate to severe PD (III–V)

Moderate to advanced PD

200

15

Bara-Jimenez et al.,
2003

Twelve alcoholic hepatic
cirrhosis and hepatic
encephalopathy; 3 alcoholic
hepatic cirrhosis; 3 fatty liver
(alcoholic) without cirrhosis; 1
healthy

Birkmayer and
Hornykiewicz, 1964

19

Baldy-Moulinier et al.,
1977

PD

Not
Not given
given

15

Argyelan et al., 2008

10 PD, 1 post-encephalitis
lethargica

Birkmayer and
Hornykiewicz, 1962

11

Aebert, 1967

Acute hepatic
encephalopathy in cirrhotic
patients with gastrointestinal
bleeding

9

4

Abramsky and
Goldschmidt, 1974

Diagnosis

Baronti et al., 1992

N

References

TABLE 3 | The human experience with IV levodopa.

None
mentioned

Ro 4–4602
(benserazide)

None

None
mentioned

None
mentioned

Carbidopa

Carbidopa

None
mentioned

None
mentioned

None mentioned

None mentioned

MAO inhibitor
(Ro-4/2637), caffeine, or
euphyllin

None mentioned

None mentioned

Terguride (dopamine
agonist); domperidone
in 4 subjects

KW-6002 (Adenosine
A2A receptor
antagonist)

None mentioned

None mentioned

None mentioned

None mentioned

None
mentioned

None
mentioned

Concomitant drugs

PDI

50 mg

50 mg

50–150 mg
infusions twice a
week for 2 weeks

25 mg, once or
twice a week, for
up to 3 years

50–150 mg

Variable,
26–55 mg/h (from
5:00 a.m. until end
of day’s study)

Infusion of “optimal
dose levodopa”

125 mg

Not given

75–1375 mg

For several days
(between 3 and 5
days depending on
the patient)

Total dose

Not mentioned

50 mg

150 mg

“Slow infusion”

150 mg

55 mg/h

725 ± 65 ng/mL

125 mg bolus

0.83 mg/kg/h

No side effects mentioned

(Continued)

No side effects mentioned. Decarboxylase inhibitor increased
the benefit of L-dopa

L-dopa caused nausea and vomiting, if combined with MAO
inhibitor. Caffeine or Euphyllin could reduce L-dopa side
effects

Unclear whether L-dopa was administered without MAO
inhibitors or nialamide. Nausea, vomiting and fainting were
the major side effects which inversely correlated with the level
of benefit

No side effects mentioned

No side effects noted for L-dopa alone. For terguride plus
levodopa, subjects had mild, transient asymptomatic
orthostatic hypotension, headache, nausea, nervousness,
drowsiness, light-headedness, and epigastric distress

No side effects mentioned for L-dopa plus placebo. There
were no drug-related serious adverse events. Levodopa plus
KW-6002 appeared generally safe and well-tolerated

No effects on electroencephalogram, electrocardiogram,
humeral arterial pressure, rectal temperature, cerebral
perfusion or metabolism at this dose

No side effects mentioned. Levodopa was associated with
increases in learning-related activation in the left dorsal
premotor cortex and in the right pre-supplementary motor
area. In the former region, there was recovery of the normal
activation response by levodopa. In the latter region, there
was a treatment-mediated gain of response in that significant
learning-related activation was present only when the
patients were scanned on levodopa therapy

No side effects mentioned

Levodopa was administered intravenously with striking and
rapid improvement of the comatose state. Within 2–5 h the
patients had recovered their normal mental state

600–
1200 mg/day

75–100 mg/10–
15 min

Side effects/comments

Maximum rate

Siddiqi et al.
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6

18

40

Bruno and Bruno, 1966

20

Bruck et al., 1965

Bruno and Brigida, 1965

21

7

Braun et al., 1987

Bronaugh et al., 1975

8

Blanchet et al., 1999

5

21

Black et al., 2010a,b

12

127

Black et al., 2003

Brod et al., 2012

20

Birkmayer and
Hornykiewicz, 1961

Bredberg et al., 1990

N

References

TABLE 3 | Continued

Schizophrenia

Schizophrenia

10 PD, 10 healthy

PD (15 idiopathic, 2
secondary to encephalitis
lethargic, 2 associated with
progressive supranuclear
palsy)

PD

PD (advanced)

Idiopathic PD

PD (postmenopausal women
with mild to moderate PD)

PD

55 PD, 20 chronic tic
disorders, 52 normal

Parkinsonism (PD,
postencephalitic
parkinsonism, and vascular
parkinsonism)

Diagnosis

None
mentioned

None
mentioned

20 received haloperidol,
20 received
chlorpromazine

Haloperidol

None mentioned

None mentioned

None
mentioned

None
mentioned

None

None mentioned

SKF38393 (selective
D-1 agonist)
administered orally in
double blind, placebocontrolled, crossover
design

Estradiol

Tozadenant (SYN115)

None mentioned

None mentioned

Concomitant drugs

Carbidopa

Benserazide

Carbidopa

Carbidopa

Carbidopa

Carbidopa

None
mentioned

PDI

2 mg/kg

100–170 mg

100 mg for PD,
50 mg for healthy
individuals

calculated:30.8–
56 µg (for 7
patients, and for 6
patients who were
already on 3.0
g/day orally)

2 mg/kg

Not given

(10–80 mg/h) ×
12 h

29 ± 4 mg/10 min
twice per day

0.6426 mg/kg

2.2 mg/kg

Up to 150 mg

Total dose

2 mg/kg/5 min

2 mg/kg/5 min

50–100 mg/20–
30 min

7.7–14 µg/4 h on
top of an oral
dose of 3.0 g/day

1 mg/kg/h

1.5 mg/min

80 mg/h

(Continued)

Neuroleptic-induced parkinsonism improved in both groups.
Some improvement in antipsychotic-induced negative
symptoms. Some patients developed nausea/vomiting,
sweating, warmth/flushing, and dizziness (number not
reported). No significant change in pulse or blood pressure

No side effects mentioned for L-Dopa alone, only in
combination with Haloperidol

Nausea, lightheadedness, syncope, unpleasant sensation in
head and abdomen, and increased blood pressure by
10–20 mmHg

No side effects mentioned. Percent conjugation of L-dopa
and metabolites given

Study compared low doses of carbidopa to higher doses.
Side effects mostly related to parkinsonian symptoms
associated with lower dose of IV levodopa than the patient’s
usual oral dose

No side effects mentioned

No dyskinesias occurred with levodopa and simultaneous
SKF38393 treatment. Dyskinesias at higher, supraoptimal
doses. No side effects mentioned for L-Dopa alone: no
orthostatic changes in blood pressure; patients remained
asymptomatic throughout. Hematological parameters and
blood chemistries remained within normal limits

The threshold dose of levodopa necessary to provide definite
antiparkinsonian efficacy was reduced significantly by
17[beta]-estradiol from 29 to 21 mg

Carbidopa 200 mg was given by mouth at least an hour
before the levodopa infusion began, using the method of
Gordon et al. (2007) and a target plasma concentration of
600 ng/ml

2.882 × 10−5 ×
(140–
age) mg/kg/min
33 mg/10 min

In healthy patients at high doses: nausea, vomiting, feeling
uncomfortably hot, increased pulse rate. In PD patients at
high doses: no side effects. In healthy patients at intermediate
doses: nausea, vomiting. In PD patients at intermediate
doses, some had dyskinesias but no nausea or vomiting. At
low doses: there was some nausea in healthy patients

No side effects mentioned

Side effects/comments

1.735 mg/kg
/10 min

“slow i.v.”
Degkwitz et al.,
1960

Maximum rate
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7

48

66

75

Fasano et al., 1970a

Fasano et al., 1970b

28

Fabbrini et al., 1987

Fabbrini et al., 1988

9

10

Davis et al., 1991

Durso et al., 2000

22

Chung et al., 2010

8

14

Chung et al., 2005

Durso et al., 1997

25

Chan et al., 2004

≥22

5

Camicioli et al., 2001

Degkwitz et al., 1960

N

References

TABLE 3 | Continued

PD

PD

Idiopathic PD

Idiopathic PD

Idiopathic PD

Idiopathic PD

Psychiatric patients and
normal controls

Idiopathic PD

PD (15 with
levodopa-induced dyskinesia)

Idiopathic PD

Idiopathic PD

PD (idiopathic), functionally
independent

Diagnosis

None
mentioned

Benserazide
150 mg IV

Carbidopa

Carbidopa

Carbidopa

Carbidopa

None

Carbidopa

Carbidopa

Carbidopa

Carbidopa

Carbidopa

PDI

None mentioned

Stimulant (“anfetaminosimile”)

None mentioned

None mentioned

None mentioned

None mentioned

None mentioned

None mentioned

None mentioned

Paroxetine

None mentioned

Methylphenidate (in one
trial, compared to
levodopa alone)

Concomitant drugs

Not stated

Not stated

19.2 mg/kg

1.5 mg/kg/h for
≥16 h

150 mg bolus

150 mg bolus

50–350 mg

None mentioned:
just found “optimal
dose rate” Total of
4 consecutive
doses at the
optimal rate were
given, so highest
total dose was
4.4 mg/day

2–3 mg/kg

2.0 mg/kg/day × 4
weeks

2.35 g/day (× 3
days)

2 mg/kg

Total dose

Not stated

Not stated

2.0 mg/kg/h

1.5 mg/kg/h

150 mg bolus
13 C labeled LDOPA/12–15 min

150 mg bolus
stable
isotope-labeled
LD/12–15 min

No side effects mentioned

(Continued)

The authors say, “no side effects were reported” with IV
levodopa, whereas chronic oral levodopa dosing (without
benserazide) produced side effects in 87% of patients
(“psychic disturbances,” dyskinesias, nausea, vomiting, and
orthostatic hypotension)

No side effects mentioned

No side effects mentioned

Average reduction in systolic blood pressure was 22 mmHg
(14, 10–40). No prolonged cardiac arrhythmias were noted
during infusion or subsequent 6-h monitoring

No side effects mentioned

No side effects mentioned

Modest worsening of motor scores after levodopa stopped.
Patients with unpredictable motor fluctuations have higher
requirements for levodopa, both orally and intravenously,
compared to those with simple wearing-off phenomena

1.1 mg/kg/10 min

Bolus (at least,
≤10 min)

No side effects mentioned

No side effects mentioned. No serious adverse effects

No side effects mentioned

Apart from bothersome dyskinesias in one patient, patients
did not report side effects or difficulties with treatments. No
effect on heart rate or diastolic blood pressure, but L-Dopa
led to a drop in systolic blood pressure. The drop in systolic
blood pressure caused by L-Dopa was reduced when
methylphenidate was administered alongside L-Dopa. No
changes in mood, anxiety, arousal, or concentration before or
after medications. Motor Unified Parkinson’s Disease
Response Scores were improved, as were tapping rates for
both sides and both walking steps and rate

Side effects/comments

1.5 mg/kg/h

1.0 mg/kg/h

1.6 mg/kg/h (×
2 h × 3 days)

2 mg/kg/h

Maximum rate
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8

20

Gancher et al., 1987

Gerstenbrand and
Pateisky, 1963

30

20

11

Friedhoff et al., 1963

Gerstenbrand and
Prosenz, 1965

7

Feigin et al., 2003

1

7

Feigin et al., 2002

Gerstenbrand and
Pateisky, 1962

7

Feigin et al., 2001

33

25

Fehling, 1966

Gancher et al., 1988

N

References

TABLE 3 | Continued

Two with Huntington’s
Disease who had
reserpine-induced
parkinsonism; remaining
subjects had postencephalitic
parkinsonism, vascular or PD

PD, postencephalitic
parkinsonism and vascular
parkinsonism

Parkinsonism due to
post-encephalitis lethargica

PD (9 de novo, 7 stable
responders, 17 fluctuating)

PD (5 de novo, 4 stable, 11
fluctuating)

Not given

PD

PD

PD

PD

Diagnosis

None
mentioned

None
mentioned

None
mentioned

Carbidopa

Carbidopa

None
mentioned

None
mentioned

None
mentioned

None
mentioned

None

PDI

MAO inhibitors

Isocarboxazid (MAO
inhibitor)

None mentioned

None mentioned

None mentioned

None mentioned

None mentioned

None mentioned

None mentioned

None mentioned

Concomitant drugs

25–200 mg

50–75 mg/day for a
few days, or with a
few days interval
between
injections,. up to
6–8 injections total

200 mg

0.8–3.0 mg/kg/h
total (0.4 to
1.5 mg/kg/h × 2 h)

1–4 mg/kg

Not given

Varied

Varied

Not given

1.5 mg/kg

Total dose

100–200 mg/20–
30 min
(“infusion”),
25–75 mg/5 min
(“injection”),
100 mg po

Not given

100 mg/20–
40 min

1.5 mg/kg/h

0.5–0.8 mg/kg/h
(lasting 2–5 h) for
untreated PD. For
treated PD, rate
approximated
usual oral LD
dose

2.5 mg/kg

100 mg/h

100 mg/h

100 mg/h (mean,
67.1 ±
25.6 mg/h)

1.5 mg/kg over
13 min
(6.9 mg/kg/h)

Maximum rate

(Continued)

L-dopa side effects included: sensation of warmth in head,
worsening of chorea in 2 Huntington’s Disease subjects,
nausea/vomiting, change in blood pressure beyond
20 mmHg, vertigo, syncope, unpleasant sensation in head
and abdomen, and urge to urinate. Subjects underwent 14
days of pretreatment with MAO-inhibitors

L-dopa side effects included nausea, vomiting, blood
pressure instability, and heat sensation. Subjects were
pretreated with a MAO inhibitor (isocarboxazid) one tablet bid
for 10–14 days

Increased systolic blood pressure by 10 mmHg, mild
mydriasis

No side effects mentioned

No side effects reported for IV L-dopa Infusions lasting 2–5 h.
After oral levodopa, 2 of 5 de novo PD patients became
nauseated (without emesis)

No side effects mentioned

Levodopa impaired aspects of sequence learning
performance in non-demented PD patients; worsening in
declarative score during motor sequence learning task
suggests levodopa may have negative effects on aspects of
cognitive processing linked to target retrieval. Levodopa also
decreased activation of occipital association cortex during
motor sequence learning

No side effects mentioned

No side effects mentioned

Levodopa did not differ from placebo in terms of clinical
improvement. Levodopa caused a brief period of nausea in 9
patients and vomiting in 2 patients. Levodopa and placebo
did not differ in their effects on blood pressure

Side effects/comments
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9

6

Hashizume et al., 1987

13

8

Hartvig et al., 1991

Henry et al., 1976

7

25

Gragnoli et al., 1977

Hardie et al., 1986

6

Gordon et al., 2007

20

6

Goldstein et al., 1999

Hardie et al., 1984

5

[-.6pt] Goetz et al., 1998

14

10

Gillin et al., 1973

Gründig et al., 1969

N

References

TABLE 3 | Continued

Depression, otherwise
healthy

Healthy

Healthy

PD (on-off fluctuators)

Idiopathic PD

9 PD, 5 normal

8 healthy; 8 Diabetes
Mellitus; 9 essential obesity

Healthy

Healthy

PD w/daily visual
hallucinations

Mild to moderate depression
(4 bipolar depression, 4
unipolar affective disorder, 1
cyclothymic personality, 1
borderline personality)

Diagnosis

Carbidopa

None
mentioned

1 subject
given
benserazide

PDI used but
not specified

Carbidopa or
benserazide

None
mentioned

None
mentioned

Carbdiopa

None
mentioned

None mentioned

None mentioned

None mentioned

None mentioned

Apomorphine
(dopaminergic agonist)

None mentioned

None mentioned

None mentioned

None mentioned

None mentioned

None mentioned

Carbidopa

Carbidopa

Concomitant drugs

PDI

50 mg (after a
week’s interval 6
pts got iv 50 mg
DOPS or 100 mg
L-DOPA without
carbidopa)

25 mg bolus

5.5 mg or 11 mg

1280 mg (up to 16
h)

up to 1500 mg/day

50 mg (control) to
100 mg

Not clear, possibly
1.5 mg/kg

Infusion over
90 min (total dose
estimated at
∼1100 mg)

99–118.8 µg/kg
(0.33 µg/min/kg ×
5–6 h)

6 mg/kg
(1.5 mg/kg/h × 4 h)

25–50 mg

Total dose

50 mg/5 min

25 mg (bolus in
20 mL saline)

10 mg bolus

32–80 mg/h

80 mg/h

100 mg

(Continued)

No nausea, vomiting, hypertension, or “other untoward side
effects” The study was designed to “avoid such peripheral
side effects by pretreating the patients with carbidopa.” IV
levodopa was associated with reduced learning compared
with chronic oral treatment and placebo infusions. No
significant changes were found in heart rate/rhythm or blood
pressure between levodopa and placebo

No nausea (except for one patient who was given oral
levodopa); authors suggest that L-dopa undergoes
decarboxylation and sulfation continuously even when
administered intravenously

No side effects mentioned

No side effects mentioned

Dystonia and chorea. 4 patients experienced significant sleep
benefit

No side effects mentioned

None of the subjects suffered nausea or showed other signs
of intolerance, or significant variations in blood pressure
during the experiment. In diabetics and obese subjects, IV
L-dopa causes a less marked human growth hormone
increase than in control subjects, with diabetics having more
of an increase than obese subjects

No significant side effects; none of the side effects were
above 1 (mild). Side effects included cold hands, mild
irritability, headaches, nausea, stomach aches, but there
were no significant differences between side effects reported
by subjects on levodopa and those with placebo infusions

Not given

1.5 mg/kg/10 min

No side effects mentioned. Authors suggest an enzymatic
gut-blood barrier for detoxifying exogenous dopamine and
delimiting autocrine/paracrine effects of endogenous
dopamine generated in a “third catecholamine system”

The authors tried to intentionally produce hallucinations in
patients who had daily hallucinations with their usual
treatment at home. IV doses were added to their oral
medications. No patients developed hallucinations even
though baseline dyskinesias persisted during the infusions

Pre-REM infusions of L-dopa delayed the onset of REM sleep
while infusion at REM onset shortened the length of the REM
period. No detectable mood or side effects were noted
except that three subjects had non-symptomatic reductions
in blood pressure without change in pulse rate 5–25 min
following the infusion

Side effects/comments

0.33 µg/min/kg

1.5 mg/kg/h

50 mg/2 min

Maximum rate
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10

34

33

Kobari et al., 1995

Lucas et al., 1975

9 PD, 6 PSP (progressive
supranuclear palsy)

18 healthy; 6 hypopituitarism;
9 chromophobe adenoma

16 idiopathic PD, 6 PSP
(progressive supranuclear
palsy), 5 olivopontocerebellar
atrophy, 7 arteriosclerotic
parkinsonism

PD

15

Idiopathic PD

PD

Kobari et al., 1992

6

Jaffe et al., 1987

Not given

PD

9

Ingvarsson, 1965b

depression: long-standing,
refractory (diagnosis unclear)

14

3

Ingvarsson, 1965a

PD

12

1

Horai et al., 2002

25 PD, 6 dystonia

Ko et al., 2013

31

Hirschmann and Mayer,
1964b

PD

PD

Juncos et al., 1990

10

Hirschmann and Mayer,
1964a

7

11

Hirano et al., 2008

Diagnosis

Juncos et al., 1987

N

References

TABLE 3 | Continued

None

Carbidopa

None
mentioned

Carbidopa

Carbidopa

Carbidopa

None
mentioned

None
mentioned

Stopped

None

None
mentioned

Carbidopa

PDI

None mentioned

None mentioned

None mentioned

None mentioned

None mentioned

None mentioned

None mentioned

None mentioned

None mentioned

MAO inhibitor

None mentioned

None mentioned

Concomitant drugs

100 mg

1 mg/kg

1 mg/kg

Not given

1.6 mg/kg

24 h/day × 6–13
days

≥2 h (at least
300 mg)

50 mg iv

10–50 mg/day for
weeks

100 mg/h × 19
days

25–50 mg;
25 mg/day for 21
days; proceeded to
year-long weekly
and then monthly
injections of
unspecified amount

25–50 mg

Not given

Total dose

100 mg bolus
(1.5 h after 25g
arginine infusion)

2 mg/kg/h

2 mg/kg/h

Not given, but
see note

7.1 ± 7.6 mg/h

∼1.5 mg/kg
/10 min
(corrected for
MW of L-Dopa
instead of MW of
L-Dopa methyl
ester (LDME))

2.5 mg/min

50 mg

50 mg/10 min

100 mg/h

Not stated

50 mg

0.56 mg/kg/h

Maximum rate

No side effects mentioned

(Continued)

No significant changes in arterial blood pressure or heart rate.
No side effects mentioned. Different patterns of regional
cerebral blood flow response to levodopa in PD vs. PSP
using xenon-enhanced CT

No significant changes were noted in local cerebral blood
flow after the administration of levodopa in patients with PSP

No side effects mentioned. Reportedly used same protocol
as Mure et al. (2012) and Hirano et al. (2008)

Dyskinesia

Motor fluctuations were markedly reduced with IV LDME. All
patients noted an improvement in their condition during
LDME treatment; reported benefits included improved sleep,
attenuation of early morning akinesia or dystonia. There was
no clinical or laboratory evidence of LDME toxicity

One subject had mild dyskinesia. IV infusion of levodopa can
affect the electroretinogram in patients with PD, indicating
that the human retina is sensitive to changes in the systemic
levels of levodopa and that this drug or its metabolite cross
the blood-retinal barrier

IV levodopa “abolishes asthmatic stridor”

In one case, a sudden improvement in a concomitant
asthmatic stridor was observed. “Depression” and “physical
symptoms” improved in patients who were classified as
depressed but may have had PD as well

Total dose ≈ 45,600mg. No side effects mentioned

No side effects mentioned

“No measurable, problematic side effects on the heart or
circulation occurred with a slow IV injection of 25–50 mg”

No side effects mentioned

Side effects/comments
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8

18

Maricle et al., 1995b

Maricle et al., 1998

11

10

10

Matussek et al., 1966

McGeer and Zeldowicz,
1964

3

15

Maricle et al., 1995a

Marion et al., 1986

N

References

TABLE 3 | Continued

PD

Depression and healthy
subjects

PD

Idiopathic PD

idiopathic PD (and
Fluctuating motor response)

Idiopathic PD

Diagnosis

None
mentioned

None
mentioned

Benserazide

None

Carbidopa

Carbidopa

PDI

None mentioned

None mentioned

None mentioned

Domperidone

None mentioned

None mentioned

Concomitant drugs

Not given

25–50 mg,
50–100 mg

755–1750 mg/12 h

2 mg/kg daily × 2
days

2 mg/kg daily × 3
days

2 mg/kg

Total dose

5 mg/min

Not given

150 mg/10 min

1 mg/kg/h

1 mg/kg/h

1 mg/kg/h

Maximum rate

(Continued)

Three patients who were given L-Dopa intravenously
experienced nausea when infusion rate increased to
5 mg/min; but all pts tolerated 2 mg/min with no noticeable
side effects, except for one patient who reported
light-headedness immediately following the infusion

Headache, nausea

No significant side effects mentioned. The patients did not
experience any major discomfort or inconvenience during the
course of the infusions and were pleased with their improved
motor performance. Infusions were given for 6 h on day 1,
and 12 h on day 2. One patient had mild dyskinesia. The
number of on-off switches decreased and the duration of
“on” periods increased in all three patients during the infusion
periods compared to oral therapy. IV infusion of levodopa
(with PDI) can give reproducible periods of constant mobility
in selected patients for up to 5 consecutive days. One patient
felt a feeling of “euphoria” after initial infusion. Another patient
had a symptomatic fall of blood pressure from 140/80 mm Hg
to 70/30 mm Hg when rate was at 99 mg/h of levodopa, so
the infusion rate was decreased to 60 mg/h

No significant side effects. Authors believe, “A significant
mood response after a 2-day levodopa holiday supports the
hypothesis that pharmacologic tolerance may be involved in
this process and that sensitization may appear after a
relatively brief period of abstinence form levodopa even in the
first year of levodopa therapy”

Effect on mood and anxiety was dose responsive. Six of 8
patients had mood response (increase in mood score greater
than 20%) during high dose infusion. Reduction of anxiety
began shortly after onset of high-dose infusion. Peak effect
on anxiety occurred 30 min after infusion had been stopped
and was followed by precipitous increase in anxiety. Patients
had little insight into discrepancy between their subjective
reports and how they appeared to observers during their
dyskinetic and agitated, but relatively euphoric state

An elevation in mood ratings was seen for all 15 patients.
(Mood ratings were an average of 40 before infusion, 60
during, and 42 after infusion). Mean anxiety decreased during
the infusion (from 57 initially to 38 during infusion, and then
increased to 62 after the infusion). Emotional fluctuations
were seen in all patients, while only a third of the patients had
a history of probable mood swings

Side effects/comments
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12

8

23

4

29

12

8

17

Moorthy et al., 1972

Mouradian et al., 1987a

Mouradian et al., 1987b

Mouradian et al., 1988

Mouradian et al., 1990

Mure et al., 2012

Nardini et al., 1970

9

61

Metzel, 1965

Nutt et al., 1984

4

Metman et al., 1999

3

25

Metman et al., 1997

Nisijima et al., 1997

N

References

TABLE 3 | Continued

Idiopathic PD

Neuroleptic malignant
syndrome (NMS)

PD

PD

PD

Idiopathic PD

Idiopathic PD

PD

Organic heart disease
undergoing routine
catheterization

PD

PD

Advanced PD

Diagnosis

Carbidopa

None
mentioned

None
mentioned

None
mentioned

Carbidopa

Carbidopa

Carbidopa

Carbidopa

None
mentioned

None
mentioned

Carbidopa

Carbidopa

PDI

None mentioned

Two patients infused
with dantrolene

None mentioned

None mentioned

None mentioned

None mentioned

None mentioned

None mentioned

None mentioned

MAO inhibitor

None mentioned

None mentioned

Concomitant drugs

Total between
2200–7200 mg,
(infusions were
continued for
20–36 h)

50–100 mg/day

25 mg

1.13 ±
0.41 mg/kg/h
(duration not
reported)

1.0 ± 0.1 mg/kg/h
× up to 12 days

200 mg

Optimal dose
infusion (not
quantified)

Up to 11 days, 24
h/day

100–200 mg (avg.
144 mg)

Not given

413–483 mg (64 ±
5 mg/h × 7 h)

Max dose is
45–540 mg
(15–180 mg/10 min
× up to 3 doses)

Total dose

Severe dyskinesia in one patient. The patients moved around
the ward and exercised freely due to IV L-dopa. Eating a
high-protein meal during levodopa infusion is associated with
a decline in the clinical response to the infused levodopa
without any alteration in the plasma concentration
110 mg/h with
carbidopa,
200 mg/h without
carbidopa

(Continued)

No side effects mentioned. Symptoms of NMS decreased
dramatically. Authors write, “Levodopa, particularly in
injectable form, should be more positively used for
pharmacotherapy in patients with NMS”

Not given

Asthenia, insomnia, anxiety, headache, increased “tensori,”
restlessness, disorientation and confusion. No side effects in
arterial pressure, digestive problems, liver or renal function

Doses titrated to achieve maximal Unified Parkinson’s
Disease Rating Score response without causing dyskinesia.
No significant changes in regional cerebral blood flow

Not given

25 mg “slow
infusion,” 1.5 3 mg/kg/h

Minimal dyskinesias, with 1.0 mg/kg/h as the dyskinesia
threshold dose

No side effects mentioned

No side effects mentioned; no cardiovascular complications.
There was no discernible alteration in the motor response to
intravenous levodopa at any time during the period of
physical activity

Maximum rate provided in Juncos et al. (1990), who also give
number of subjects as 28. No side effects

Nausea (5 pts), accompanied by vomiting (in 2 pts). The
nausea was severe at 10–15 min after the start of the L-dopa
infusion. Serious arrhythmias were not seen. Two patients
had ventricular premature contractions. The effects on the
cardiovascular system observed were slight. blood pressure
showed a tendency to fall in some patients during the initial
5 min after injection and to rise later to values higher than the
control values. No serious complications were seen. The
authors’ observations seem to indicate that treatment with
L-dopa is not particularly dangerous in patients with organic
heart disease

No side effects mentioned. In some cases dopa was
combined with a MAO-inhibitor

variable;
apparently up to
200 mg/10 min
as a loading dose

200 mg/10 min

Optimal dose rate
lasting at least
16 h

1.8 mg/kg/h

200 mg/10 min

Not given

No side effects mentioned

No side effects mentioned

180 mg/10 min

69 mg/h

Side effects/comments

Maximum rate
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18

Nutt et al., 1997b

13

1

20

Ogawa et al., 2012

Oishi et al., 1996

23

11

Nutt et al., 1997a

Nutt and Woodward,
1986

16

Nutt et al., 1995

4

17

Nutt et al., 1994

Nutt and Nygaard, 2001

19

Nutt et al., 1993

18

27

Nutt et al., 1992

Nutt et al., 2002

8

Nutt et al., 1988

12

9

Nutt et al., 1985

Nutt et al., 2001

N

References

TABLE 3 | Continued

Parkinsonism (PD, vascular
parkinsonism)

PD

Idiopathic PD (and fluctuating
response)

All 4 had DRD
(dopa-responsive dystonia); 2
had PD in addition to DRD

Idiopathic PD

Idiopathic PD

PD

Idiopathic PD (and fluctuating
response)

Idiopathic PD

Idiopathic PD

PD

PD

PD (with fluctuating response)

Idiopathic PD

Diagnosis

None
mentioned

None
mentioned

Carbidopa

Carbidopa

Carbidopa

Carbidopa

Carbidopa

Carbidopa

Carbidopa

Carbidopa

Carbidopa

Carbidopa

Carbidopa

Carbidopa

PDI

None mentioned

Dai-kenchu-tou (5-HT3
receptor agonist)

None mentioned

None mentioned

Domperidone

None mentioned

Domperidone

None mentioned

None mentioned

None mentioned

None mentioned

None mentioned

None mentioned

None mentioned

Concomitant drugs

50 mg

Not mentioned

3.0–13.2 mg/kg
(0.5–2.2 mg/kg/h ×
6 h)

2 mg/kg daily × 2
days

4 mg/kg total
(1 mg/kg/h × 4 h)

2 or 3 mg/kg

4 mg/kg total
(2 mg/kg daily × 2
days)

2 mg/kg

2 mg/kg

2 h (average
1.96 mg/kg, max
3.2 mg/kg)

33.3 mg/kg/ 21 h

0, 0.4, 0.8, 1.6,
2.4 mg/kg/h × 2 h

0.28–2.54 mg/kg

Max 1250 mg

Total dose

50 mg bolus

75 mg/kg daily
boluses, duration
not reported

2.2 mg/kg/h

1 mg/kg/h

1 mg/kg/h

1 or 1.5 mg/kg/h

1 mg/kg/h

1.51 mg/kg/h

mean
0.98 mg/kg/h

Max:
1.6 mg/kg/h,
mean:
0.98 mg/kg/h

1.6 mg/kg/h

2.4 mg/kg/h

1.27 mg/kg/h

2.12 mg/kg/h

Maximum rate

No side effects mentioned

(Continued)

IV levodopa was used as a treatment for neuroleptic
malignant syndrome

2 patients exhibited a brief burst of mobility and dyskinesia
lasting minutes. Generally, with the onset of mobility, the
patients had a brief burst of tremor, or tremor mixed with
dyskinesia, and then became mildly dyskinetic

No side effects mentioned. “In one subject, two doses of
levodopa and a night’s sleep abolished her dystonia and
restored normal tapping rate”

The same dose of L-Dopa produced progressively more
severe dyskinesia with long-term L-dopa therapy but did not
increase the duration of dyskinesia in patients. However,
increasing the dose of L-dopa in subjects with dyskinesia
does not increase the severity of dyskinesia but does
increase the duration of dyskinesia

No side effects mentioned. Mood, anxiety, and blood
pressure were measured at 30-min intervals for 7 h total, and
there was no mention of any effects of levodopa on anxiety or
blood pressure

Levodopa therapy was able to restore tapping speed almost
to normal

Mild dyskinesia

Some nausea and lightheadedness

2 patients developed nausea and one experienced
lightheadedness (only during post-holiday levodopa
infusions). In general, 2-h levodopa infusions were
“well-tolerated,” with no medical complications during the
levodopa holiday

Short infusions were well-tolerated, long infusions less so.
Two subjects had dyskinesia during long infusion and two
others suffered from confusion, although short infusions were
well-tolerated by all subjects

Mild dyskinesia

Post-improvement worsening. Some mild dyskinesia

Mild dyskinesia

Side effects/comments
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14

13

Puritz et al., 1983

36

8

28

Rinne and Sonninen,
1968

Roberts et al., 1995

Robertson et al., 1989

10

10

Pullman et al., 1988

Quinn et al., 1984

Not
Not given
given

Poewe, 1993

3

5

Peppe et al., 1991

Quinn et al., 1982

11

Pazzagli and Amaducci,
1966

12 healthy elderly and 16
healthy young subjects

Normal

Idiopathic PD (24) and
post-encephalitic PD (12)

PD

PD

6 healthy; 7 progressive
autonomic failure and multiple
system atrophy (MSA)

5 PD and 5 healthy

PD

PD

Depression candidates for
ECT who were responsive to
Iproniazid

3

Pare and Sandler, 1959

Diagnosis

N

References

TABLE 3 | Continued

Both with and
without
carbidopa

Carbidopa

None

Carbidopa or
benserazide

Benserazide

None
mentioned

Carbidopa

None
mentioned

Carbidopa

None
mentioned

None
mentioned

PDI

None mentioned

None mentioned

None mentioned

None mentioned

None mentioned

None mentioned

None mentioned

None mentioned

Domperidone

None mentioned

Iproniazid

Concomitant drugs

50 mg bolus

50 mg

1.5 mg/kg

Variable; highest
total dose appears
to be 187 mg/h ×
8.8 h × 12 doses

Not given (only that
treatment was
given for about 8 h
at unspecified rate)

99.875 mg

Not given

Not given

770 mg/day × 5
days, (given
110 mg/kg/h × 7 h)

60 mg, 90 mg, or
120 mg

12.5–137.5 mg
(25 mg–275 mg
racemic)

Total dose

Pulse and blood pressure fell, but to the same degree as with
oral levodopa; “slight and transient” postural faintness
(orthostasis); coldness of the limbs; nausea and vomiting;
dyskinesias. No patient complained of palpitations during the
infusions, and no arrhythmias were detected. Authors assert,
“Continuous intravenous infusion of levodopa turns out to be
the most effective way of abolishing the off state during a
substantial period of the day”

150 mg bolus in
≥2 subjects; all
subjects received
100–200 mg over
10 min, then up
to 187 mg/h
(mean 125 mg/h)

50 mg
bolus/5 min

50 mg/5 min

None mentioned

None mentioned

(Continued)

Pulse and blood pressure changes were comparable
between levodopa and placebo. Common adverse effects
included nausea (47%), vomiting (31%), vertigo (19%),
headache (33%), sweating (44%), and anxiety (22%);
frequency of adverse effects not reported with placebo

No side effects mentioned. The patients with severe on-off
fluctuations had dramatic benefit. Authors write, “Intravenous
levodopa infusion obviously overcomes many of the
problems of intermittent oral treatment”

Not given

1.5 mg/kg/10 min

No subjects experienced adverse effects during the infusion
although one vomited after discontinuation of L-dopa. For
one dosage and rate: change in AVP (plasma arginine
vasopressin), blood pressure and heart rate are given. No
significant effects of L-Dopa on mean blood pressure in
normal subjects, but lowered blood pressure of MSA
patients. No effect heart rate or AVP levels in basal state.
Author suggests “L-Dopa should not be prescribed for
patients with MSA”

No side effects mentioned

No side effects mentioned. From a table entry in a review
article

No side effects mentioned

Hypotension, nausea, vomiting, somnolence, and mild
sedation accompanied by feeling euphoric

No side effects mentioned. DL-DOPA was used

Side effects/comments

1.175 mg/min

Varied rates from
high, middle, and
low (actual dose
not specified)

not given

110 mg/h (mean
70 mg/h)

Not given

275 mg bolus of
DL-DOPA

Maximum rate
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15

42

Sohn et al., 1994

29

Siddiqi et al., 2015

9

5

Shoulson et al., 1975

Skalabrin et al., 1998

1

Shinoda et al., 2013

1

Sage and Mark, 1991

6

20

Ruggieri et al., 1988

Schuh and Bennett,
1993

1

Rosin et al., 1979

5

14

Rodriguez et al., 1994

Sasahara et al., 1980b

N

References

TABLE 3 | Continued

PD

Advanced PD

Tourette syndrome and
healthy controls

PD

PD

Advanced idiopathic PD

PD

PD

Idiopathic PD

Idiopathic PD and carcinoma
of the rectum

Asymmetric PD

Diagnosis

Carbidopa

Carbidopa

Carbidopa

Carbidopa

None
mentioned

Carbidopa

None
mentioned

Carbidopa

Carbidopa

Carbidopa

Carbidopa

PDI

None mentioned

None mentioned

None

None mentioned

None mentioned

None mentioned

None mentioned

None mentioned

Domperidone

None mentioned

Domperidone.
Apomorphine given
subcutaneously

Concomitant drugs

36–150 mg

Not given

0.6426 mg/kg

Not given (duration
of 3 h at
unspecified rate)

75 mg

57.6 mg/kg, (given
24 h/day × 3–8
days)

50 mg

240 mg/day (during
nighttime)

(360–1200 mg/day)
× 3 days

4320 mg highest
total dose for a day
(given between
1200 and
4320 mg/day for 7
days)

960 mg to 2200 mg
(60–100 mg/h ×
16–22 h)

Total dose

150 mg/10 min

No side effects mentioned
(Continued)

Doses escalated until a maximum of 3.0 mg/kg/h infusion
rate was achieved, OR the subject experienced maximum
dyskinesia, or developed nausea or hypotension

No significant difference in pulse, blood pressure, or
orthostatic change between IV levodopa and placebo when
co-administered with carbidopa

2.882 × 10−5 ×
(140–
age) mg/kg/min
2.6–3.0 mg/kg/h

No side effects mentioned. No significant changes in pulse
rate or blood pressure occurred

Patient developed neuroleptic malignant syndrome (NMS)
due to underdosing of IV levodopa as a result of dilution in
extracorporeal circulation during open heart surgery

L-Dopa induced dyskinesia, but only occurs because of the
progression of PD. No other side effects mentioned

No side effects mentioned

No side effects mentioned. Oral carbidopa/levodopa was
given during the daytime while IV levodopa was administered
at night. Nighttime infusions produced immediate benefit of a
good night’s sleep, and nighttime levodopa infusions also
reduced patient’s daytime motor fluctuations. Authors
suggest the levodopa infusion rate required to produce the
best results was between 40 and 45 mg/h

The patients were given constant IV L-dopa infusion for 12 h
× 3 days. Mild somnolence, nausea, and occasional vomiting
were the only side effects reported. There was an increase in
blood pressure (probably due to domperidone). Maximum
optimal drug rate ranged from 30–104 mg/h with mean
53.5 mg/h

No side effects or adverse effects: no “undue” abdominal
distention, nausea, vomiting, cardiac arrhythmia, or
hypotension

None mentioned

Side effects/comments

Not given

50 mg bolus

2.4 mg/kg/h

50 mg/20 min

30 mg/h

1200 mg/day x 3
days

180 mg/h

250 mg/h (for
short infusion).
Up to 100 mg/h
(for long infusion)

Maximum rate
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16

32

6

8

Takubo et al., 2003

Tedroff et al., 1990

Tedroff et al., 1992

8

9

Stocchi et al., 1992

Takeuchi et al., 1993

18

Stocchi et al., 1986

1

25

Souvatzoglou et al.,
1973

Sunami et al., 2000

N

References

TABLE 3 | Continued

Idiopathic PD

PD and healthy

Malignant syndrome (MS)

Healthy

Akathisia

PD

Idiopathic PD

Healthy

Diagnosis

Benserazide

Benserazide

Some
subjects given
unspecified
PDI

None
mentioned

None
mentioned

Carbidopa

Carbidopa

None
mentioned

PDI

None mentioned

None mentioned

None mentioned

None mentioned

None mentioned

None mentioned

None mentioned

None mentioned

Concomitant drugs

200 mg

0.9 mg

2440 mg/day (for
patient before
study began)

50 mg

25 mg/day × 8
days, followed by
lower infusions

100 up to
≥600 mg/days

1080–3750 mg
total
(360–1250 mg/day
for 3 days)

1 mg, 5 mg,
12.5 mg, 25 mg, or
100 mg

Total dose

200 mg/6 min

0.9 mg bolus

Not given

50 mg for
>10 min

25 mg/day

(Continued)

No side effects mentioned; brain uptake of [β-11 C]-L-DOPA
was inversely correlated to the sum of large neutral amino
acids in plasma

No side effects mentioned

No side effects mentioned. Suggests the following dosages
of IV levodopa in the treatment of malignant syndrome:
300–600 mg/24 h or 100–200 mg/3 h three times a day

Study of mechanisms of orthostatic hypotension in L-dopa
treated PD. At rest, the systolic blood pressure was
significantly lowered by L-dopa administration, but diastolic
blood pressure, heart rate, and calf blood flow were not
significantly altered by L-dopa administration. Spontaneous
muscle sympathetic nerve activity was significantly higher
than that before administration. Results support hypothesis
that L-dopa and/or its metabolites act on peripheral blood
vessels at sympathetic nerve terminal, thereby inducing
orthostatic hypotension

No side effects mentioned. Authors believe IV levodopa
treatment “would be useful in reducing the persistent
neurotoxicity (lethargy, hypersomnia, depression, agitation,
akathisia, and confusion) associated with interferon-alpha”

No side effects mentioned. Blood pressure and pulse were
assessed every 15 min, and no mention was made of any
changes to either blood pressure or pulse

No side-effects, except for a mild somnolence during the first
day, were recorded. Blood pressure, cardiac electric
morphology, and rhythm did not change significantly during
the study. Authors argue IV infusion could be a precious form
of rating the real single individual’s L-dopa needs. They write,
“L-dopa infusion remains a good technique in the overall
evaluation of the parkinsonian patient and indispensable in
particular situations like post-operative recovery and intensive
care”

1250 mg/day × 3
days

200 mg boluses
or 400 mg/h. For
3 subjects:
“optimum rate”
for 12 h × 3 days

2 cases at 100 mg of mild nausea lasting 5–10 min. In no
instance were any cardiac effects observed. Serum growth
hormone is stimulated by 25 mg IV L-dopa

Side effects/comments

5 mg/ml L-dopa
infused, blood
samples drawn at
10 min intervals
over 3–4 h.
(therefore the
lowest max rate
possible was
5 mg/ml/min)

Maximum rate
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17

PD

Healthy

PD

PD

Idiopathic PD

PD

30 PD, 5 controls

PD

Idiopathic PD

None

None
mentioned

None
mentioned

Carbidopa

Carbidopa

None
mentioned

None
mentioned

None
mentioned

None
mentioned

Carbidopa

Carbidopa

PDI

Summary of published studies reporting IV levodopa use in humans, 1959 to early 2015.

Total
2760

6

Worth et al., 1988

Total references 142

180

Voller, 1968

10

14

Verhagen Metman et al.,
1998b

Zsigmond et al., 2012

6

35

Umbach and Baumann,
1964

Verhagen Metman et al.,
1998a

Not
Not given
given

Umbach, 1966

30

125

Tzavellas and Umbach,
1967

Umbach and Tzavellas,
1965

10

Torstenson et al., 1997

PD

10

Tedroff et al., 1996

Diagnosis

N

References

TABLE 3 | Continued

None

None mentioned

In unspecified number of
patients, MAO inhibitors
(isocarboxazid 10 mg TID
or nialamide 25 mg BID)

None mentioned

Dextromethorphan

Propylhexadrine
(amphetamine)

None mentioned

Amphetamine

Propylhexadrine
(amphetamine)

None mentioned

None mentioned

Concomitant drugs

281.25 mg

840 µg/kg

25 mg twice per
week

≥150 mg

up to 65 ± 14 mg

50 mg

100 mg in 13
patients and
100 mg in 17
patients

Not given

Not given

5 mg/kg (2 mg/kg
+ 2 mg/kg/h ×
1.5 h)

3 mg/kg

Total dose

375 mg/h for
45 min

7 µg/kg/min

Not given

150 mg/10 min

Not given

Not given

Not given

Not given

Not given

0.5 mg/kg/min
over 4 min as
bolus; then
2 mg/kg/h

0.5 mg/kg/min
bolus for 5 min

Maximum rate

No side effects mentioned. In 2 patients who had previously
discontinued oral levodopa/carbidopa due to nausea, high
doses of IV levodopa were well-tolerated and relieved
symptoms

Mean plasma renin activity fell by 50%; significant increase in
urinary sodium excretion and effective renal plasma flow;
mean diastolic blood pressure fell with no reflex tachycardia.
Mean diastolic pressure fell on infusion of L-dopa. Trends
toward fall in mean systolic pressure and rise in mean pulse
rate on infusion of L-dopa, but these were not significantly
different from changes occurring on saline infusion

Increase of PR interval (on electrocardiogram), tachycardia,
sweating, nausea. All these were mild and transient so that
no experiment was interrupted

No side effects mentioned

No side effects mentioned. Brief IV infusions (10 min each, 4 h
for a total of 9–12 infusions)

L-Dopa alone caused drop in blood pressure

Patients after stereotaxic surgery. Specific L-dopa side
effects are not mentioned, but it is said that higher doses
caused more severe side effects

No side effects for L-dopa alone. Reported side effects are
caused by combination treatment with amphetamines.
L-dopa and amphetamine treatment of akinetic Parkinsonism
patients with and without stereotaxic surgery. It is not clear
how many were treated only with L-Dopa

No side effects mentioned. Subjects received a combination
of L-dopa and propyl-hexedrin (MAO inhibitor)

No side effects mentioned

Before the study, one patient was excluded due to
levodopa-induced nausea. Authors write, “levodopa is still
the most effective symptomatic treatment for PD, and
compared with the various dopamine agonists available, is
well-tolerated by most patients. The finding that the capacity
for levodopa to produce increased synaptic dopamine levels
is most profound in the more denervated regions of the
striatum means that levodopa is acting preferentially at the
site of dopaminergic denervation”

Side effects/comments
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DISCUSSION

(Connolly and Lang, 2014). When given with adequate PDI
pretreatment, IV levodopa has minimal if any cardiovascular
effects (Siddiqi et al., 2015).
The safety of IV levodopa is important for patients but also
for regulatory review. Changing the route of administration
of any drug in a study traditionally necessitates submitting
an IND application if changing the route of administration
“significantly increases the risks . . . associated with the use
of the drug product” [§21 CFR 312.2(b)(iii)]. The data from
our review of the literature suggest that IV administration of
levodopa does not significantly increase the associated risks of
levodopa in comparison to oral administration. In summary,
studies conducted throughout the past half century support the
safety of IV levodopa administration in human patients.

The existing literature strongly supports the safety of IV
levodopa, which has been used in humans for more than half
a century (Pare and Sandler, 1959). IV levodopa has been
administered to over 2700 human subjects. Despite infusion rates
as high as 5.0 mg/kg/h and boluses as large as 200 mg, there are
no recorded instances of death or of other serious adverse effects
of IV levodopa, nor have there been documented cases of other
serious side effects, such as psychosis, that might limit its use in
humans. Milder side effects, the most significant of which are
nausea and vomiting, were most prominent with rapid infusions
in the range of 1–2 mg/kg or 100–200 mg over less than 15 min
(Bruno and Bruno, 1966; Fehling, 1966; Rinne and Sonninen,
1968; Moorthy et al., 1972; Quinn et al., 1984; Black et al., 2003).
These conclusions are supported by safety data from other
species. The Registry of Toxic Effects of Chemical Substances
reports the lowest published toxic dose of levodopa in any nonhuman species as 2.5 mg/kg, referring to a subtle behavioral effect
on a learning measure in a mouse (NIOSH and Biovia, 2015)1 .
The lowest IV levodopa dose that was lethal to half of subjects
(LD50) was “>100 mg/kg” in rats. In mice, the LD50 ranges
from 450 mg/kg (administered intravenously) to 4449 mg/kg
(administered subcutaneously). Typical human doses are in the
range of only 1 mg/kg; thus, human studies with IV levodopa
administer doses substantially lower than those dangerous to
nonhuman mammals.
In summary, IV levodopa has similar efficacy and side
effects as oral levodopa (Connolly and Lang, 2014) and
dopamine agonists (Bonuccelli and Ceravolo, 2008). These
include gastrointestinal (nausea, vomiting, and abdominal
discomfort) and neuropsychiatric effects (sedation, dyskinesias).
Nausea and orthostatic hypotension, side effects of both IV and
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1 RTECS

reported the lowest toxic dose as “100 µg/kg,” but the dose in the cited
reference was actually 100 µg/g = 100 mg/kg (Takahara et al., 1980).

oral levodopa, are largely blocked by PDIs and are less common
in patients accustomed to dopamimetic treatment. The other side
effects are infrequent and neither serious nor life-threatening
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